Management of Stage IIIA (N2) Non-Small Cell Lung Cancer

Erin A Gillaspie; Dennis A Wigle

doi:10.1016/j.thorsurg.2016.04.001

Management of Stage IIIA (N2) Non-Small Cell Lung Cancer

Thorac Surg Clin. 2016 Aug;26(3):271-85. doi: 10.1016/j.thorsurg.2016.04.001.

Authors

Erin A Gillaspie¹, Dennis A Wigle²

Affiliations

¹ Division of Thoracic Surgery, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA.
² Division of Thoracic Surgery, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA. Electronic address: wigle.dennis@mayo.edu.

PMID: 27427522
DOI: 10.1016/j.thorsurg.2016.04.001

Abstract

There is no consensus as to the optimal management of IIIA (N2) non-small cell lung cancer, nor for the role of surgery in treating this disease stage. Clinical trial evidence struggles to keep up with technology advancement and the evolution of expert opinion. Despite advances in chemotherapeutic regimens, methods of delivery for radiation, and less invasive surgical techniques, survival for patients with stage IIIA-N2 malignancies remains poor. Further developments in both will stimulate and maintain controversy in the field for years to come.

Keywords: Adjuvant; N2; Neoadjuvant; Non–small cell lung cancer; PORT; Stage IIIA; Surgery.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung / pathology
Carcinoma, Non-Small-Cell Lung / therapy*
Disease Management*
Humans
Lung Neoplasms / pathology
Lung Neoplasms / therapy*
Neoplasm Staging*